751. Methotrexate-associated lymphoproliferative disorder.
- Author
-
Kaneko Y
- Subjects
- Age Factors, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Female, Herpesvirus 4, Human, Humans, Immunity, Cellular, Lymphoproliferative Disorders pathology, Male, Methotrexate therapeutic use, Prognosis, Risk Factors, Antirheumatic Agents adverse effects, Lymphoproliferative Disorders etiology, Methotrexate adverse effects
- Abstract
Methotrexate-associated lymphproliferative disorder (MTX-LPD) is a rare but critical complication developing in patients treated with methotrexate. Now that methotrexate is an anchor drug in the management of rheumatoid arthritis and become commonly used, MTX-LPD cases have increased. Many things has been unclear such as incidence, demographic characters, and risk factors. However, as the researches increased, several interesting topics has been demonstrated like associations with Epsteiin-Barr virus and with cell-mediated immunity. This report reviews newly the latest findings and future challenges on MTX-LPD.
- Published
- 2017
- Full Text
- View/download PDF